Contributions
Abstract: P1160
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Neuropsychology
Background: One factor hindering the more widespread use of cognitive testing for people with MS is the need for a tester to administer the tests.
Objective: To undertake a proof of concept study assessing the feasibility and sensitivity of a fully automated speech recognition version of the Symbol Digit Modalities Test (auto-SDMT) in detecting abnormalities in processing speed in people with MS.
Methods: A sample of 50 people with MS and 32 demographically matched healthy control (HC) subjects were tested with the auto-SDMT and the Brief International Cognitive Assessment in MS (BICAMS).
Results: The percentages of MS participants impaired on the auto-SDMT and the traditional oral SDMT were 34% and 32%, respectively. Excellent convergent validity was found between the two tests in both the MS (r = -0.806, p < 0.001) and HC (r = -0.629, p < 0.001) groups. The auto-SDMT had a similar sensitivity and specificity to the traditional oral SDMT in predicting overall impairment on the BICAMS.
Conclusions: The auto-SDMT is a sensitive measure for detecting processing speed deficits in people with MS. The test uses speech recognition technology thereby eliminating the need for a human tester and making it suitable for people with upper limb disability. Additional advantages include standardized administration across multiple sites and the automatic provision of results.
Disclosure: Viral Patel: nothing to disclose
Lingkai Shen: nothing to disclose
Jonathan Rose: nothing to disclose
Anthony Feinstein has received speaker honoraria from Merck Serono, Teva Pharmaceuticals Industries Ltd., Novartis, and Biogen Idec; serves on the editorial boards of Multiple Sclerosis Journal; receives publishing royalties for The Clinical Neuropsychiatry of Multiple Sclerosis (Cambridge University Press, 2007); chairs the Medical Advisory Committee for the Multiple Sclerosis Society of Canada; conducts neuropsychiatric evaluation, cognitive testing, and brain imaging in neuropsychiatry in his clinical practice, and receives research support from the Multiple Sclerosis Society of Canada.
Abstract: P1160
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Neuropsychology
Background: One factor hindering the more widespread use of cognitive testing for people with MS is the need for a tester to administer the tests.
Objective: To undertake a proof of concept study assessing the feasibility and sensitivity of a fully automated speech recognition version of the Symbol Digit Modalities Test (auto-SDMT) in detecting abnormalities in processing speed in people with MS.
Methods: A sample of 50 people with MS and 32 demographically matched healthy control (HC) subjects were tested with the auto-SDMT and the Brief International Cognitive Assessment in MS (BICAMS).
Results: The percentages of MS participants impaired on the auto-SDMT and the traditional oral SDMT were 34% and 32%, respectively. Excellent convergent validity was found between the two tests in both the MS (r = -0.806, p < 0.001) and HC (r = -0.629, p < 0.001) groups. The auto-SDMT had a similar sensitivity and specificity to the traditional oral SDMT in predicting overall impairment on the BICAMS.
Conclusions: The auto-SDMT is a sensitive measure for detecting processing speed deficits in people with MS. The test uses speech recognition technology thereby eliminating the need for a human tester and making it suitable for people with upper limb disability. Additional advantages include standardized administration across multiple sites and the automatic provision of results.
Disclosure: Viral Patel: nothing to disclose
Lingkai Shen: nothing to disclose
Jonathan Rose: nothing to disclose
Anthony Feinstein has received speaker honoraria from Merck Serono, Teva Pharmaceuticals Industries Ltd., Novartis, and Biogen Idec; serves on the editorial boards of Multiple Sclerosis Journal; receives publishing royalties for The Clinical Neuropsychiatry of Multiple Sclerosis (Cambridge University Press, 2007); chairs the Medical Advisory Committee for the Multiple Sclerosis Society of Canada; conducts neuropsychiatric evaluation, cognitive testing, and brain imaging in neuropsychiatry in his clinical practice, and receives research support from the Multiple Sclerosis Society of Canada.